米氮平与路优泰治疗抑郁症对照研究

Study on Mirtazapine and Neurostan in the Treatment of Depression

目的评价米氮平与路优泰治疗抑郁症的疗效和不良反应。方法将符合CCM D-3抑郁症诊断标准的门诊和住院患者共60例,随机分为两组,分别给予米氮平(n=30,研究组)和路优泰(n=30,对照组),疗程6周,用汉密尔顿抑郁量表(HRSD)、汉密尔顿焦虑量表(HAMA),临床疗效总评量表的病情严重程度(CG I-S I)和副反应量表(TESS)评定疗效和副反应。结果米氮平与路优泰对抑郁症疗效接近(χ2=0.232,P>0.05);但显效时间二者有显著性差异,研究组平均(4.2±1.7)天,对照组平均(11.3±4.2)天(P<0.01);副反应无显著性差异(P>0.05)。结论米氮平是一种安全有效的新一代抗抑郁药。

Objective To compare the efficacy and side effects between mirtazapine and neurostan in the treatment of depression.Method A total of 60 inpatients and outpatients with a diagnosis of depression according to CCMD-3 were randomly assigned to mirtazapine group（n=30）as the research teams and neurostan group（n=30）served as controls for six weeks.Effects and side reactions were evaluated with HRSD,HAMA,CGI-SI and TESS before and after the treatment.Result The efficacy of mirtazapine was similar to that of neurostan（χ2=0.232,P0.05）;There was significant difference in the effectual time between mirtazapine and neurostan group,The research group took effect on（4.2±1.7） days,the other needed（11.3±4.2） days（P〈0.01）;there was no significant difference in side effect between two groups（P〈0.05）;Conclusion Mirtazapine is an effective and safe antidepressant.